Epidemiology of gout and chondrocalcinosis

Reumatismo

Volumn 63, Issue 4, 2011, Pages 207-220

  Ciancio, G ^a   Bortoluzzi, A ^a   Govoni, Marcello ^a  

^a UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Chondrocalcinosis; CPPD; Epidemiology; Gout; Incidence; Prevalence

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM PYROPHOSPHATE; CYCLOSPORIN; DIURETIC AGENT; LOOP DIURETIC AGENT; THIAZIDE DIURETIC AGENT; URATE;

AGING; ALCOHOL CONSUMPTION; CHONDROCALCINOSIS; COMORBIDITY; DIAGNOSTIC VALUE; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG MEGADOSE; DRUG USE; ENDOCRINE DISEASE; FIBROCARTILAGE; GOUT; HEMOCHROMATOSIS; HUMAN; HYALINE CARTILAGE; HYPERPARATHYROIDISM; HYPERTENSION; HYPERURICEMIA; HYPOMAGNESEMIA; INCIDENCE; JOINT INJURY; KIDNEY DISEASE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; METABOLIC DISORDER; MORBIDITY; MORTALITY; OSTEOARTHRITIS; PREVALENCE; REVIEW; RISK FACTOR; SEASONAL VARIATION;

BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHONDROCALCINOSIS; DIABETES COMPLICATIONS; EVIDENCE-BASED MEDICINE; FOOD HABITS; GOUT; HUMANS; HYPERTENSION; INCIDENCE; ITALY; KIDNEY DISEASES; LIFE STYLE; METABOLIC SYNDROME X; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; WORLD HEALTH;

EID: 84856589938     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (132)

1. Doherty M. New insights into the epidemiology of gout. Rheumatology (Oxford) 2009; 48: ii2-ii8.
2. Wijnands JM, Boonen A, Arts IC, et al. Large epidemiologic studies of gout: challenges in diagnosis and diagnostic criteria. Curr Rheumatol Rep 2011; 13: 167-74.
3. Smith EU, Diaz-Torne C, Perez-Ruiz F, March LM. Epidemiology of gout: an update. Best Pract Res Clin Rheumatol 2010; 24: 811-27.
4. Zhang W, Doherty M, Bardin T, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis 2011; 70: 563-70.
5. Salaffi F, De Angelis R, Grassi W. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. Clin Exp Rheumatol 2005; 23: 819-28.
6. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008; 58: 26-35.
7. Hall AP, Barry PE, Dawber TR, McNamara PM. Epidemiology of gout and hyperuricemia. A long-term population study. Am J Med 1967; 42: 27-37.
8. O'Sullivan JB. Gout in a New England town. A prevalence study in Sudbury, Massachusetts. Ann Rheum Dis 1972; 31: 166-9.
9. Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis 2002; 40: 37-42.
10. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population. Arthritis Rheum 2011.
11. Portis AJ, Laliberte M, Tatman P, et al. High prevalence of gouty arthritis among the Hmong population in Minnesota. Arthritis Care Res (Hoboken) 2010; 62: 1386-91.
12. Currie WJ. Prevalence and incidence of the diagnosis of gout in Great Britain. Ann Rheum Dis 1979; 38: 101-6.
13. Harris CM, Lloyd DC, Lewis J. The prevalence and prophylaxis of gout in England. J Clin Epidemiol 1995; 48: 1153-8.
14. Mikuls TR, Farrar JT, Bilker WB, et al. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005; 64: 267-72.
15. Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008; 67: 960-6.
16. Klemp P, Stansfield SA, Castle B, Robertson MC. Gout is on the increase in New Zealand. Ann Rheum Dis 1997; 56: 22-6.
17. Cassim B, Mody GM, Deenadayalu VK, Hammond MG. Gout in black South Africans: a clinical and genetic study. Ann Rheum Dis 1994; 53: 759-62.
18. Miao Z, Li C, Chen Y, et al. Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. J Rheumatol 2008; 35: 1859-64.
19. Nan H, Qiao Q, Dong Y, et al. The prevalence of hyperuricemia in a population of the coastal city of Qingdao, China. J Rheumatol 2006; 33: 1346-50.
20. Anagnostopoulos I, Zinzaras E, Alexiou I, et al. The prevalence of rheumatic diseases in central Greece: a population survey. BMC Musculoskelet Disord 2010; 11: 98.
21. Andrianakos A, Trontzas P, Christoyannis F, et al. Prevalence of rheumatic diseases in Greece: a cross-sectional population based epidemiological study. The ESORDIG Study. J Rheumatol 2003; 30: 1589-601.
22. Balkon N, Balkon C, Zitkus BS. Overweight and obesity: pharmacotherapeutic considerations. J Am Acad Nurse Pract 2011; 23: 61-6.
23. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290: 199-206.
24. Bhole V, de Vera M, Rahman MM, et al. Epidemiology of gout in women: fifty-two-year followup of a prospective cohort. Arthritis Rheum 2010; 62: 1069-76.
25. Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther 2010; 12: 223.
26. Cea Soriano L, Rothenbacher D, Choi HK, Garcia Rodriguez LA. Contemporary epidemiology of gout in the UK general population. Arthritis Res Ther 2011; 13: R39.
27. Elliot AJ, Cross KW, Fleming DM. Seasonality and trends in the incidence and prevalence of gout in England and Wales 1994-Ann Rheum Dis 2009; 68: 1728-33.
28. Rothenbacher D, Primatesta P, Ferreira A, et al. Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology (Oxford) 2011; 50: 973-81.
29. Arromdee E, Michet CJ, Crowson CS, et al. Epidemiology of gout: is the incidence rising? J Rheumatol 2002; 29: 2403-6.
30. De Vera M, Rahman MM, Rankin J, et al. Gout and the risk of Parkinson's disease: a cohort study. Arthritis Rheum 2008; 59: 1549-54.
31. Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 2000; 27: 1501-5.
32. Brauer GW, Prior IA. A prospective study of gout in New Zealand Maoris. Ann Rheum Dis 1978; 37: 466-72.
33. Hanova P, Pavelka K, Dostal C, et al. Epidemiology of rheumatoid arthritis, juvenile idiopathic arthritis and gout in two regions of the Czech Republic in a descriptive population-based survey in 2002-2003. Clin Exp Rheumatol 2006; 24: 499-507.
34. Padang C, Muirden KD, Schumacher HR, et al. Characteristics of chronic gout in Northern Sulawesi, Indonesia. J Rheumatol 2006; 33: 1813-7.
35. Alvarez-Nemegyei J, Medina-Escobedo M, Villanueva-Jorge S, Vazquez-Mellado J. Prevalence and risk factors for urolithiasis in primary gout: is a reappraisal needed? J Rheumatol 2005; 32: 2189-91.
36. Kramer HJ, Choi HK, Atkinson K, et al. The association between gout and nephrolithiasis in men: The Health Professionals' Follow-Up Study. Kidney Int 2003; 64: 1022-6.
37. Janssens HJ, van de Lisdonk EH, Bor H, et al. Gout, just a nasty event or a cardiovascular signal? A study from primary care. Fam Pract 2003; 20: 413-6.
38. Novak S, Melkonian AK, Patel PA, et al. Metabolic syndrome-related conditions among people with and without gout: prevalence and resource use. Curr Med Res Opin 2007; 23: 623-30.
39. Riedel AA, Nelson M, Wallace K, et al. Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol 2004; 10: 308-14.
40. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007; 116: 894-900.
41. Ioachimescu AG, Brennan DM, Hoar BM, et al. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum 2008; 58: 623-30.
42. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2010; 62: 170-80.
43. Niskanen LK, Laaksonen DE, Nyyssonen K, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004; 164: 1546-51.
44. Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 1183-90.
45. Wheeler JG, Juzwishin KD, Eiriksdottir G, et al. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med 2005; 2: e76.
46. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007; 57: 109-15.
47. Hernandez-Cuevas CB, Roque LH, Huerta-Sil G, et al. First acute gout attacks commonly precede features of the metabolic syndrome. J Clin Rheumatol 2009; 15: 65-7.
48. Tomita M, Mizuno S, Yamanaka H, et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol 2000; 10: 403-9.
49. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 2009; 61: 885-92.
50. Chen JH, Chuang SY, Chen HJ, et al. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum 2009; 61: 225-32.
51. Krishnan E, Svendsen K, Neaton JD, et al. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008; 168: 1104-10.
52. De Leonardis F, Govoni M, Colina M, et al. Elderly-onset gout: a review. Rheumatol Int 2007; 28: 1-6.
53. Kim KY, Ralph Schumacher H, Hunsche E, et al. A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003; 25: 1593-617.
54. Harrold LR, Yood RA, Mikuls TR, et al. Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Dis 2006; 65: 1368-72.
55. De Souza AW, Fernandes V, Ferrari AJ. Female gout: clinical and laboratory features. J Rheumatol 2005; 32: 2186-8.
56. Bomalaski JS, Schumacher HR. Podagra is more than gout. Bull Rheum Dis 1984; 34: 1-8.
57. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987; 82: 421-6.
58. Lin KC, Lin HY, Chou P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. J Rheumatol 2000; 27: 1045-50.
59. Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol 2011; 23: 192-202.
60. Scott JT, Pollard AC. Uric acid excretion in the relatives of patients with gout. Ann Rheum Dis 1970; 29: 397-400.
61. Emmerson BT, Nagel SL, Duffy DL, Martin NG. Genetic control of the renal clearance of urate: a study of twins. Ann Rheum Dis 1992; 51: 375-7.
62. Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol 2007; 3: 443-9.
63. So A, Thorens B. Uric acid transport and disease. J Clin Invest 2010; 120: 1791-9.
64. Le MT, Shafiu M, Mu W, Johnson RJ. SLC2A9-a fructose transporter identified as a novel uric acid transporter. Nephrol Dial Transplant 2008; 23: 2746-9.
65. Dehghan A, Kottgen A, Yang Q, et al. Association of three genetic loci with uric acid concentration and risk of gout: a genomewide association study. Lancet 2008; 372: 1953-61.
66. Merriman TR, Dalbeth N. The genetic basis of hyperuricaemia and gout. Joint Bone Spine 2011; 78: 35-40.
67. Choi HK, Zhu Y, Mount DB. Genetics of gout. Curr Opin Rheumatol 2010; 22: 144-51.
68. Urano W, Taniguchi A, Anzai N, et al. Sodium-dependent phosphate cotransporter type 1 sequence polymorphisms in male patients with gout. Ann Rheum Dis 2010; 69: 1232-4.
69. Phipps-Green AJ, Hollis-Moffatt JE, Dalbeth N, et al. A strong role for the ABCG2 gene in susceptibility to gout in New Zealand Pacific Island and Caucasian, but not Maori, case and control sample sets. Hum Mol Genet 2010; 19: 4813-9.
70. Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417: 447-52.
71. Graessler J, Graessler A, Unger S, et al. Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum 2006; 54: 292-300.
72. Morcillo S, Rojo-Martinez G, Martin-Nunez GM, et al. Trp64Arg polymorphism of the ADRB3 gene predicts hyperuricemia risk in a population from southern Spain. J Rheumatol 2010; 37: 417-21.
73. Chen SY, Chen CL, Shen ML, Kamatani N. Trends in the manifestations of gout in Taiwan. Rheumatology (Oxford) 2003; 42: 1529-33.
74. Yamanaka H. Gout and hyperuricemia in young people. Curr Opin Rheumatol 2011; 23: 156-60.
75. Choi HK, Atkinson K, Karlson EW, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004; 350: 1093-103.
76. Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ 2008; 336: 309-12.
77. Choi JW, Ford ES, Gao X, Choi HK. Sugarsweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2008; 59: 109-16.
78. Choi HK, Willett W, Curhan G. Coffee consumption and risk of incident gout in men: a prospective study. Arthritis Rheum 2007; 56: 2049-55.
79. Choi HK, Gao X, Curhan G. Vitamin C intake and the risk of gout in men: a prospective study. Arch Intern Med 2009; 169: 502-7.
80. Dalbeth N, Wong S, Gamble GD, et al. Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial. Ann Rheum Dis 2010; 69: 1677-82.
81. Dalbeth N, Gracey E, Pool B, et al. Identification of dairy fractions with anti-inflammatory properties in models of acute gout. Ann Rheum Dis 2010; 69: 766-9.
82. Fam AG, Stein J, Rubenstein J. Gouty arthritis in nodal osteoarthritis. J Rheumatol 1996; 23: 684-9.
83. Chang SJ, Ko YC, Wang TN, et al. High prevalence of gout and related risk factors in Taiwan's Aborigines. J Rheumatol 1997; 24 1364-9.
84. Chou CT, Lai JS. The epidemiology of hyperuricaemia and gout in Taiwan aborigines. Br J Rheumatol 1998; 37: 258-62.
85. Mijiyawa M, Oniankitan O. Risk factors for gout in Togolese patients. Joint Bone Spine 2000; 67: 441-5.
86. Choi HK, Atkinson K, Karlson EW, et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004; 363: 1277-81.
87. Williams PT. Effects of diet, physical activity and performance, and body weight on incident gout in ostensibly healthy, vigorously active men. Am J Clin Nutr 2008; 87: 1480-7.
88. Shulten P, Thomas J, Miller M, et al. The role of diet in the management of gout: a comparison of knowledge and attitudes to current evidence. J Hum Nutr Diet 2009; 22 3-11.
89. Zhang Y, Woods R, Chaisson CE, et al. Alcohol consumption as a trigger of recurrent gout attacks. Am J Med 2006; 119: 800 e13-8.
90. Fam AG. Gout, diet, and the insulin resistance syndrome. J Rheumatol 2002; 29: 1350-5.
91. Choi HK, De Vera MA, Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology (Oxford) 2008; 47: 1567-70.
92. Sarafidis PA, Nilsson PM. The metabolic syndrome: a glance at its history. J Hypertens 2006; 24: 621-6.
93. Hjortnaes J, Algra A, Olijhoek J, et al. Serum uric acid levels and risk for vascular diseases in patients with metabolic syndrome. J Rheumatol 2007; 34: 1882-7.
94. Puig JG, Prior C, Martinez-Ara J, Torres RJ. Familial nephropathy associated with hyperuricemia in Spain: our experience with 3 families harbouring a UMOD mutation. Nucleosides Nucleotides Nucleic Acids 2006; 25: 1295-300.
95. Emmerson B. Hyperlipidaemia in hyperuricaemia and gout. Ann Rheum Dis 1998; 57: 509-10.
96. Lee J, Sparrow D, Vokonas PS, et al. Uric acid and coronary heart disease risk: evidence for a role of uric acid in the obesityinsulin resistance syndrome. The Normative Aging Study. Am J Epidemiol 1995; 142: 288-94.
97. Rathmann W, Funkhouser E, Dyer AR, Roseman JM. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Ann Epidemiol 1998; 8: 250-61.
98. Dessein PH, Shipton EA, Stanwix AE, et al. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 2000; 59: 539-43.
99. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991; 266: 3008-11.
100. Muscelli E, Natali A, Bianchi S, et al. Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens 1996; 9: 746-52.
101. Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 2005; 165: 742-8.
102. Hunter DJ, York M, Chaisson CE, et al. Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study. J Rheumatol 2006; 33: 1341-5.
103. Hagos Y, Stein D, Ugele B, et al. Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J Am Soc Nephrol 2007; 18: 430-9.
104. Abbott KC, Kimmel PL, Dharnidharka V, et al. New-onset gout after kidney transplantation: incidence, risk factors and implications. Transplantation 2005; 80: 1383-91.
105. Mazzali M. Uric acid and transplantation. Semin Nephrol 2005; 25: 50-5.
106. Yu TF, Gutman AB. Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man. J Clin Invest 1959; 38: 1298-315.
107. Caspi D, Lubart E, Graff E, et al. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum 2000; 43: 103-8.
108. Cohen SD, Kimmel PL, Neff R, et al. Association of incident gout and mortality in dialysis patients. J Am Soc Nephrol 2008; 19: 2204-10.
109. Felson DT, Anderson JJ, Naimark A, et al. The prevalence of chondrocalcinosis in the elderly and its association with knee osteoarthritis: the Framingham Study. J Rheumatol 1989; 16: 1241-5.
110. Sanmarti R, Panella D, Brancos MA, et al. Prevalence of articular chondrocalcinosis in elderly subjects in a rural area of Catalonia. Ann Rheum Dis 1993; 52: 418-22.
111. Neame RL, Carr AJ, Muir K, Doherty M. UK community prevalence of knee chondrocalcinosis: evidence that correlation with osteoarthritis is through a shared association with osteophyte. Ann Rheum Dis 2003; 62: 513-8.
112. Ramonda R, Musacchio E, Perissinotto E, et al. Prevalence of chondrocalcinosis in Italian subjects from northeastern Italy. The Pro.V.A. (PROgetto Veneto Anziani) study. Clin Exp Rheumatol 2009; 27: 981-4.
113. Derfus BA, Kurian JB, Butler JJ, et al. The high prevalence of pathologic calcium crystals in pre-operative knees. J Rheumatol 2002; 29: 570-4.
114. Nalbant S, Martinez JA, Kitumnuaypong T, et al. Synovial fluid features and their relations to osteoarthritis severity: new findings from sequential studies. Osteoarthritis Cartilage 2003; 11: 50-4.
115. Viriyavejkul P, Wilairatana V, Tanavalee A, Jaovisidha K. Comparison of characteristics of patients with and without calcium pyrophosphate dihydrate crystal deposition disease who underwent total knee replacement surgery for osteoarthritis. Osteoarthritis Cartilage 2007; 15: 232-5.
116. Zhang Y, Terkeltaub R, Nevitt M, et al. Lower prevalence of chondrocalcinosis in Chinese subjects in Beijing than in white subjects in the United States: the Beijing Osteoarthritis Study. Arthritis Rheum 2006; 54: 3508-12.
117. Netter P, Bardin T, Bianchi A, et al. The ANKH gene and familial calcium pyrophosphate dihydrate deposition disease. Joint Bone Spine 2004; 71: 365-8.
118. Zhang Y, Brown MA. Genetic studies of chondrocalcinosis. Curr Opin Rheumatol 2005; 17: 330-5.
119. Doherty M, Dieppe P. Crystal deposition disease in the elderly. Clin Rheum Dis 1986; 12: 97-116.
120. Doherty M, Watt I, Dieppe PA. Localised chondrocalcinosis in post-meniscectomy knees. Lancet 1982; 1: 1207-10.
121. Yashiro T, Okamoto T, Tanaka R, et al. Prevalence of chondrocalcinosis in patients with primary hyperparathyroidism in Japan. Endocrinol Jpn 1991; 38: 457-64.
122. Pritchard MH, Jessop JD. Chondrocalcinosis in primary hyperparathyroidism. Influence of age, metabolic bone disease, and parathyroidectomy. Ann Rheum Dis 1977; 36: 146-51.
123. Dymock IW, Hamilton EB, Laws JW, Williams R. Arthropathy of haemochromatosis. Clinical and radiological analysis of 63 patients with iron overload. Ann Rheum Dis 1970; 29: 469-76.
124. Pawlotsky Y, Le Dantec P, Moirand R, et al. Elevated parathyroid hormone 44-68 and osteoarticular changes in patients with genetic hemochromatosis. Arthritis Rheum 1999; 42: 799-806.
125. Huaux JP, Geubel A, Koch MC, et al. The arthritis of hemochromatosis. A review of 25 cases with special reference to chondrocalcinosis, and a comparison with patients with primary hyperparathyroidism and controls. Clin Rheumatol 1986; 5: 317-24.
126. Timms AE, Sathananthan R, Bradbury L, et al. Genetic testing for haemochromatosis in patients with chondrocalcinosis. Ann Rheum Dis 2002; 61: 745-7.
127. Richette P, Ayoub G, Lahalle S, et al. Hypomagnesemia associated with chondrocalcinosis: a cross-sectional study. Arthritis Rheum 2007; 57: 1496-501.
128. Jones AC, Chuck AJ, Arie EA, et al. Diseases associated with calcium pyrophosphate deposition disease. Semin Arthritis Rheum 1992; 22: 188-202.
129. McLeod J. Gout and fibrositis in cold weather. Med J Aust 1972; 1: 943.
130. Arber N, Vaturi M, Schapiro JM, et al. Effect of weather conditions on acute gouty arthritis. Scand J Rheumatol 1994; 23: 22-4.
131. Schlesinger N, Gowin KM, Baker DG, et al. Acute gouty arthritis is seasonal. J Rheumatol 1998; 25: 342-4.
132. Gallerani M, Govoni M, Mucinelli M, et al. Seasonal variation in the onset of acute microcrystalline arthritis. Rheumatology (Oxford) 1999; 38: 1003-6.